NEW YORK (GenomeWeb) – Crown Bioscience has acquired Molecular Response's patient-derived xenograft (PDX) business for an undisclosed amount, the companies announced today. 

Crown is acquiring Molecular Response's existing PDX models and 8,000 viable human tumors for model development. The tumors are from Molecular Response's viable tumor bank containing more than 140,000 cryopreserved 100 percent US tumor samples. As part of the deal, Crown will be able to select and develop additional models from Molecular Response's tumor bank. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.